Personalized neoantigen tumor vaccine
Phase 1Vaccine
Personalized neoantigen tumor vaccine is one of 173 biologic programs targeting Patients With Advanced Solid Tumors. It is currently in Phase 1.
5
Indications
6
Total Trials
5
Active Trials
172
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
335 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Personalized neoantigen tumor vaccine
RRuijin Hospital
Phase 1
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Active Comparator
ModernaPreclinical
Sulfonylureas
Eli LillyPreclinical
HS-20093
Jiangsu Hansoh Pharmaceutical Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Cancer2 trials
Patients With Advanced Solid Tumors1 trial
Acute Myeloid Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Phase 1[1]
- Company
- RRuijin Hospital